Trauson Holdings: China's next med device M&A target

Trauson Holdings, China's largest maker of pelvic reconstruction plates and other trauma surgery-related orthopedic products, is likely one of the next big medical device acquisition targets in that country, Bloomberg predicts. The reason: Trauson is in a space that stands to gain as China's massive elderly population expands in the coming years. Medtronic ($MDT) is already thinking ahead in this way, the article notes, with its recent $755 million purchase of China Kanghui Holdings, an orthopedic implant maker. China's orthopedic implant sales will virtually double by 2015, to $2.7 billion, according to Frost & Sullivan data cited by Bloomberg. More than 181 million senior citizens in China have artificial joints and implanted spinal devices, according to the story. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.